Literature DB >> 8724893

Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation.

N Perico1, D Ostermann, M Bontempeill, M Morigi, C S Amuchastegui, C Zoja, E Akalin, M H Sayegh, G Remuzzi.   

Abstract

Colchicine, which inhibits cell microtubule assembly by preventing polymerization of tubulin monomers, inhibits cell-mediated immune responses and promotes long-term survival of major histocompatibility complex-incompatible renal allografts in rats. Here we evaluated the effect of blocking cell microtubule assembly by colchicine on T cell and endothelial cell adhesion receptors involved in transducing signals for T cell activation. By using immunofluorescence flow cytometry analysis, evidence is presented that colchicine, in a dose-dependent fashion, downregulated L-selectin and leukocyte function-associated antigen-1, but not CD2 and CD44 on the surface of naive human peripheral blood lymphocytes. This effect was confirmed in two subsets of T lymphocytes, namely, CD45RA- and CD45RO-positive cells. However, colchicine did not influence the rapid shedding of L-selectin from T lymphocytes exposed to activating stimuli. Colchicine inhibited expression of interleukin-2 receptor on activated T lymphocytes. This effect was observed when T lymphocytes were stimulated with both anti-CD3 and anti L-selectin monoclonal antibodies. Colchicine also inhibited lymphocyte function in vitro as documented by inhibition of the human mixed lymphocyte response in a dose-dependent fashion. Moreover, colchicine downregulated surface expression of intercellular adhesion molecule-1 and E-selectin on activated human umbilical vein endothelial cells. These results indicate that blocking cell microfubule assembly inhibits surface expression of adhesion molecules on T cells and endothelial cells, and provides insights into the complex mechanisms of the action of colchicine in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724893     DOI: 10.1681/ASN.V74594

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  14 in total

1.  Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.

Authors:  Daria B Crittenden; R Aaron Lehmann; Laura Schneck; Robert T Keenan; Binita Shah; Jeffrey D Greenberg; Bruce N Cronstein; Steven P Sedlis; Michael H Pillinger
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

2.  Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease.

Authors:  Luca Liberale; Fabrizio Montecucco; Jean-Claude Tardif; Peter Libby; Giovanni G Camici
Journal:  Eur Heart J       Date:  2020-08-14       Impact factor: 29.983

3.  Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial.

Authors:  Nina C Raju; Qilong Yi; Mark Nidorf; Nick D Fagel; Rajesh Hiralal; John W Eikelboom
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

4.  Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials.

Authors:  Yi Chen; Hongzhou Zhang; Yuxin Chen; Meng Li; Wei Luo; Yue Liu; Yang Fu; Huasong Xia; Cong Xu; Yu Jiang; Yanqing Wu
Journal:  Clin Rheumatol       Date:  2022-02-09       Impact factor: 2.980

Review 5.  The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events.

Authors:  Serban Maierean; Richard Webb; Maciej Banach; Mohsen Mazidi
Journal:  Eur Heart J Open       Date:  2022-06-14

6.  Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Shao-Huan Lan; Chi-Kuei Hsu; Chih-Cheng Lai; Shen-Peng Chang; Li-Chin Lu; Shun-Hsing Hung; Wei-Ting Lin
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 7.  Colchicine for secondary prevention of cardiovascular disease.

Authors:  Stefan M Nidorf; John W Eikelboom; Peter L Thompson
Journal:  Curr Atheroscler Rep       Date:  2014-03       Impact factor: 5.113

Review 8.  Colchicine in the Management of Acute and Chronic Coronary Artery Disease.

Authors:  Nadia Bouabdallaoui; Jean-Claude Tardif
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

9.  Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.

Authors:  Jean-Claude Tardif; Nadia Bouabdallaoui; Philippe L L'Allier; Daniel Gaudet; Binita Shah; Michael H Pillinger; Jose Lopez-Sendon; Protasio da Luz; Lucie Verret; Sylvia Audet; Jocelyn Dupuis; André Denault; Martin Pelletier; Philippe A Tessier; Sarah Samson; Denis Fortin; Jean-Daniel Tardif; David Busseuil; Elisabeth Goulet; Chantal Lacoste; Anick Dubois; Avni Y Joshi; David D Waters; Priscilla Hsue; Norman E Lepor; Frédéric Lesage; Nicolas Sainturet; Eve Roy-Clavel; Zohar Bassevitch; Andreas Orfanos; Gabriela Stamatescu; Jean C Grégoire; Lambert Busque; Christian Lavallée; Pierre-Olivier Hétu; Jean-Sébastien Paquette; Spyridon G Deftereos; Sylvie Levesque; Mariève Cossette; Anna Nozza; Malorie Chabot-Blanchet; Marie-Pierre Dubé; Marie-Claude Guertin; Guy Boivin
Journal:  Lancet Respir Med       Date:  2021-05-27       Impact factor: 30.700

10.  Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

Authors:  Nadia Bouabdallaoui; Jean-Claude Tardif; David D Waters; Fausto J Pinto; Aldo P Maggioni; Rafael Diaz; Colin Berry; Wolfgang Koenig; Jose Lopez-Sendon; Habib Gamra; Ghassan S Kiwan; Lucie Blondeau; Andreas Orfanos; Reda Ibrahim; Jean C Grégoire; Marie-Pierre Dubé; Michelle Samuel; Olivier Morel; Pascal Lim; Olivier F Bertrand; Simon Kouz; Marie-Claude Guertin; Philippe L L'Allier; Francois Roubille
Journal:  Eur Heart J       Date:  2020-11-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.